Symptom Management Overview

As more patients with cancer use cannabis to treat symptoms and for the cancer itself, oncologists need to understand these medicines’ potential benefits and side effects, explains Declan Walsh, MD, MSc.
According to Ann M. Berger, PhD, MSN, APRN, AOCNS, FAAN, Professor and Dorothy Hodges Olson Endowed Chair in Nursing, College of Nursing, University of Nebraska Medical Center, Omaha, there is an urgent need for further research in this area to alleviate these symptoms and enhance quality of life among survivors of all types of cancer.
Recent surveys have revealed that up to 25% of patients with cancer take some form cannabis, but oncologists and other medical providers are often unaware that their patients are using medical or recreational cannabis.

This symptom management article describes the approach to rasburicase-induced hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency, which may occur intravascularly in this patient population.

For patients diagnosed with cancer, the annual incidence of VTE is approximately 20%, and the risk for VTE in this patient population is estimated to be 7 times higher than in the general population.

Targeting and inhibiting the vascular endothelial growth factor (VEGF)-signaling pathway has become an integral modality in the treatment of a variety of malignancies, including renal-cell carcinoma (RCC); glioblastoma; hepatocellular carcinoma; gastrointestinal stromal tumors; and colorectal, lung, gastric, and ovarian cancers.
This section provides a quick update of symptomatic conditions in oncology and their management. Readers are invited to submit brief updates following the guidelines at www.JHOPonline.com.

Results 1 - 7 of 7